NCT04177004View on ClinicalTrials.gov

Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2021

Primary Completion Date

October 27, 2025

Study Completion Date

October 27, 2025

Conditions

Allogeneic Hematopoietic Stem Cell Transplant RecipientHematopoietic and Lymphoid Cell Neoplasm

Interventions

PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo allo-HCT

DRUG

Cyclophosphamide

Given IV

DRUG

Etoposide

Given IV

RADIATION

Fractionated Stereotactic Radiation Therapy

Undergo FTBI

DRUG

Goat Milk

Given human lysozyme goat milk PO

BIOLOGICAL

Palifermin

Given IV

DRUG

Sirolimus

Given PO

DRUG

Tacrolimus

Given IV and PO

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT04177004 - Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant | Biotech Hunter | Biotech Hunter